anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A novel eudesman compound and an anti-inflammatory composition containing the same are provided to suppress NO generation and to prevent and treat inflammatory diseases without cytotoxicity. CONSTITUTION: A cosmetic composition contains eudesman compounds of chemical formula 1 as an active ingredient. In chemical formula, R is CH_3 or CH_2. The eudesman compounds are isolated from Taraxacum mongolicum. A pharmaceutical composition for preventing and treating inflammatory diseases contains the eudesman compounds as an active ingredient. An external use skin formulation for preventing and treating inflammatory contains eudesman compounds as an active ingredient.
In this group, the - usual care based upon BLS-PCS with manual titration of oxygen. In this group the SpO2 was recorded any time with FreeO2 device - recording mode.
A process for the preparation of hexapeptide of formula Tyr-d-Ala-Gly-Phe-Leu-Arg by peptide synthesis in solution provides for stage-to-stage peptide elongation by connection in specified sequence of protected or unprotected amino acids or peptides followed by removal of provisional protective groups after each stage of connection, isolation and purification of intermediate peptides, repeating the process up to obtaining completely protected hexapeptide, removal of all protective groups, isolation and chromatographic purification of final peptide. In the peptide elongation process intermediate peptides of general formula Вос-AA...AA-CPG, wherein АА...АА is a chain of from two to six adjacent amino acid residues from the sequence Tyr(SPG)-d-Ala-Gly-Phe-Leu-Arg(SPG), wherein Tyr(SPG)=Туr, Tyr(Bzl), Arg(SPG)=Arg, Arg(NO), CPG=OMe, Onbz. One of protective groups Boc or CPG can be absent. Combination of protected amino acids or peptides is carried out by carbodiimide method, and addition of unprotected arginine by means of diphenyl phosphoryl azide. The purification of intermediate peptides is carried out by extraction , recrystallization or, if necessary, by chromathography. The purification of the final peptide is carried out by recrystallization and by methods of reversed-phase chromatography, ion chromatography or by combination thereof.
PURPOSE OF REVIEW: This review summarizes key findings relating to the association between preeclampsia and retinal disorders.
RECENT FINDINGS: Preeclampsia is a major cause of maternal morbidity. Pregnant women with preeclampsia frequently describe having visual disturbances. Retinal changes can be identified on fundoscopy in most patients with preeclampsia. While retinal pathology secondary to preeclampsia usually resolves postpartum, there is growing evidence that women with preeclampsia have a higher long-term risk of developing retinal disorders after pregnancy. Pregnant women often experience visual changes. While these symptoms may be benign, careful attention should be paid to exclude retinal disorders secondary to preeclampsia. Pregnant women complaining of new-onset or worsening blurry vision, scotomata, diplopia, or photopsia require rapid and thorough evaluation to rule out hypertensive disorders. Management of preeclampsia, including administration of magnesium sulfate and delivery of the fetus, can reverse retinal pathologies in most cases.
The protein-fortified diet consists on an energy goal based on REE measurement and a protein target based on the most recent literature recommendations (1.2-2 g/kg/die) (2). Daily caloric requirement, and subsequent protein content, of patients enrolled in the intervention group will be calculated using formulas in Table 1 (10, 12, 13). For each patient will be calculated the Resting Energy Expenditure (REE) and daily protein requirement (1.2-2g/kg/die of body weight registered at the admission) and the corresponding caloric intake (1g = 4 kcal). Finally, total daily caloric intake will be calculated by adding kcal from protein (1g = 4kcal) on kcal from non-protein (50% of REE).
Fatigue is one of main symptoms in multiple sclerosis, amyotrophic lateral sclerosis, post-polio syndrome, stroke, parkinsonism as well as in the chronic fatigue syndrome. It has profound effect on quality of life and professional and social functioning and in multiple sclerosis it is described as the worst symptoms by the 50% of patients. It is defined as the difficulty in initiating and maintaining a sustained mental or physical activity. Not infrequent it is misdiagnosed as sleepiness or other symptom. Fatigue severity scale (FSS) is a time efficient and easy to apply instrument to assess the impact of fatigue on patient's life. It has been translated and validated in Turkish, Russian, Hindi, Portuguese, and many other languages. FSS is a short, nine-item self-report questionnaire. Each item is a Likert scale, scored from one to seven, where seven refers to the most severely expressed aspect of fatigue. The aim of this study is to validate the Polish-language version of the Fatigue Severity Scale (pFSS). This version has been created according to widely accepted, respective standards, including translation by two independent native Polish-language speakers with acquired knowledge of English and backward translation by two independent native English-language speakers with acquired knowledge of Polish as well as with the pretesting on ten patients.
INTRODUCTION AND HYPOTHESIS: To define the prevalence and incidence of pelvic/low back pain in patients with pelvic organ prolapse (POP).
METHODS: Patients presenting for POP to three urogynecology centers in the US, UK, and Chile were enrolled in an IRB-approved cross-sectional study assessing pain, GU, GI and sexual function symptoms. For prevalence, symptoms were noted as present if the participant recorded the symptom and reported the degree of bother as "somewhat," "a moderate amount," or "a lot." For incidence, participants were queried if the symptom's onset concurred with the POP. We also queried if they perceived the symptom was worsened by their POP.
RESULTS: Two hundred five participants were recruited: 100 from the US, 46 from the UK, and 59 from Chile. One US participant was excluded due a missing examination. The prevalence of pelvic pain was 42%. Seventy-three percent of these participants reported the onset of pelvic pain coinciding with prolapse onset, and 81% endorsed worsening pelvic pain with POP. The prevalence of low back pain was 46%, with 30% reporting the onset coincided with the onset of POP and 44% responded that prolapse worsened their pain.
CONCLUSION: A higher proportion of participants than expected endorsed pelvic/low back pain. Among patients with pelvic pain, the majority experienced symptom onset with POP onset and a worsening of pain with POP. While roughly half of participants reported low back pain; a minority correlated this to their POP. These findings highlight a high incidence of pelvic pain, challenging the perception of POP as a painless condition.
Bupivacaine liposome injectable suspension is a sterile, non-pyrogenic white to off-white preservative-free aqueous suspension consisting of multivesicular liposomes containing bupivacaine for infiltration and interscalene brachial plexus nerve block. Bupivacaine is present at a concentration of 13.3 mg/mL. After injection of bupivacaine liposome injectable suspension, bupivacaine is released from the multivesicular liposomes. Bupivacaine liposome injectable suspension is for infiltration or perineural use.

Active Ingredient

Bupivacaine is related chemically and pharmacologically to the amide-type local anesthetics. It is a homologue of mepivacaine and is related chemically to lidocaine. All three of these anesthetics contain an amide linkage between the aromatic nucleus and the amino, or piperidine group. They differ in this respect from the procaine-type local anesthetics, which have an ester linkage. Chemically, bupivacaine is 1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide with a molecular weight of 288.4. Bupivacaine has the following structural formula:

Bupivacaine Liposome Injectable Suspension

The median diameter of the liposome particles in bupivacaine liposome injectable suspension ranges from 22 to 30 μm. The liposomes are suspended in a 0.9% Sodium Chloride Injection. Each vial contains bupivacaine at a nominal concentration of 13.3 mg/mL. Inactive ingredients and their nominal concentrations are: cholesterol, 4.7 mg/mL; 1, 2-dipalmitoyl-sn-glycero-3 phospho-rac-(1-glycerol) sodium salt (DPPG), 0.9 mg/mL; tricaprylin, 2.0 mg/mL; 1, 2-dierucoylphosphatidylcholine (DEPC), 8.2 mg/mL; and phosphoric acid to adjust pH. The pH of bupivacaine liposome injectable suspension is in the range of 5.8 to 7.4.

Bupivacaine in bupivacaine liposome injectable suspension has different functional properties relative to those of the unencapsulated or nonlipid-associated bupivacaine products. Bupivacaine that is released from bupivacaine liposome injectable suspension has a different pharmacokinetic and systemic profile relative to other bupivacaine products. In addition, the nominal weight percent concentration of bupivacaine in bupivacaine liposome injectable suspension is based on bupivacaine free base rather than bupivacaine HCl (100 mg of bupivacaine HCl contains 88.6 mg of bupivacaine free base) [ see Dosage and Administration (2.1)].
The progression of idiopathic pulmonary fibrosis (IPF) is assessed through serial monitoring of forced vital capacity (FVC). Currently, data regarding the clinical significance of longitudinal changes in diffusing capacity for carbon monoxide (DLCO) is lacking. We investigated the prognostic implications of a 1-year decline in DLCO in 319 patients newly diagnosed with IPF at a tertiary hospital between January 2010 and December 2020. Changes in FVC and DLCO over the first year after the initial diagnosis were reviewed; a decline in FVC ≥ 5% and DLCO ≥ 10% predicted were considered significant changes. During the first year after diagnosis, a significant decline in FVC and DLCO was observed in 101 (31.7%) and 64 (20.1%) patients, respectively. Multivariable analysis showed that a 1-year decline in FVC ≥ 5% predicted (aHR 2.74, 95% CI 1.88-4.00) and 1-year decline in DLCO ≥ 10% predicted (aHR 2.31, 95% CI 1.47-3.62) were independently associated with a higher risk of subsequent mortality. The prognostic impact of a decline in DLCO remained significant regardless of changes in FVC, presence of emphysema, or radiographic indications of pulmonary hypertension. Therefore, serial monitoring of DLCO should be recommended because it may offer additional prognostic information compared with monitoring of FVC alone.
BACKGROUND: Heterotopic ossification (HO) is a common complication after elbow fracture surgery and can lead to severe upper extremity disability. The radiographic localization of postoperative HO has been reported previously. However, there is no literature examining the distribution of postoperative HO at the three-dimensional (3D) level. This study aimed to investigate 1) the distribution characteristics of postoperative HO and 2) the possible risk factors affecting the severity of postoperative HO at a 3D level.
METHODS: A retrospective review was conducted of patients who presented to our institution with HO secondary to elbow fracture between 13 January 2020 and 16 February 2023. Computed tomography scans of 56 elbows before elbow release surgery were reconstructed in 3D. HO was identified using density thresholds combined with manual identification and segmentation. The elbow joint and HO were divided into six regions according to three planes: the transepicondylar plane, the lateral ridge of the trochlear plane, and the radiocapitellar joint and coronoid facet plane. The differences in the volume of regional HO associated with different initial injuries were analyzed.
RESULTS: Postoperative HO was predominantly present in the medial aspect of the capsule in 52 patients (93%), in the lateral aspect of the capsule in 45 patients (80%), in the medial supracondylar in 32 patients (57%), and in the lateral supracondylar, radial head, and ulnar region in the same number of 28 patients (50%). The median and interquartile range volume of total postoperative HO was 1683 (777-4894) mm3. The median and interquartile range volume of regional postoperative HO were: 584 (121-1454) mm3 at medial aspect of capsule, 207 (5-568) mm3 at lateral aspect of capsule, 25 (0-449) mm3 at medial supracondylar, 1 (0-288) at lateral supracondylar, 2 (0-478) at proximal radius and 7 (0-203) mm3 at the proximal ulna. In the subgroups with Injury Severity Score > or = 16, Gustilo-Anderson II, normal uric acid levels, elevated alkaline phosphatase, and body mass index > or = 24, the median HO volume exceeds that of the respective control groups.
CONCLUSION: The medial aspect of the capsule was the area with the highest frequency and median volume of postoperative HO among all initial elbow injury types. Patients with higher Gustilo-Anderson grade, Injury Severity Score, alkaline phosphatase or Body Mass Index had higher median volume of postoperative HO.
In recent years, the treatment of malignant tumors has continually advanced, significantly extending the survival period of cancer patients. Tumors are increasingly present as chronic diseases over the long term, and the cardiovascular toxicity associated with cancer treatment has become increasingly prominent, severely affecting the effective treatment and survival of cancer patients. As a result, cardio-oncology has gained considerable attention as an emerging discipline. However, cardiovascular diseases in cancer patients often have an insidious onset, and early identification and treatment are frequently overlooked. Throughout the course of cancer treatment, it is crucial to reasonably apply cardiac biomarkers for risk stratification, early identification, and screening of cardiovascular diseases in patients, as well as to improve the early diagnosis and treatment levels of cardiovascular diseases in cancer patients. To this end, Cardio-Oncology Group, Chinese Society of Cardiology in conjunction with Cardiovascular Expert Committee, China Medical Doctor Association of Laboratory Medicine, organized experts in relevant fields to compile this consensus. It aims to provide a basis for clinicians to standardize the screening and management of cardiovascular toxicity related to cancer treatment through the reasonable application of cardiac biomarkers.
Cold laser used off of the body over the vulvar involved area. The device to be used in this study is the Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device. Weekly visits x 6 with 5 minute treatments over vulva and sacral nerve roots each.
Use of a vascular-endothelial protein tyrosine phosphatase (A), the nucleic acid (B) that encodes (A) or ligands (C) specific for (A), or their fragments, to produce an agent for monitoring or modulating the activity of the receptor-type tyrosine kinase Tie-2. ACTIVITY : Anti-angiogenic; antitumor; antimetastatic. MECHANISM OF ACTION : Tie-2 is involved in sprouting and remodeling of the vascular system, during embryogenesis, wound healing and pathological processes, and is a specific substrate for (A). Tie-2 or VEGFR2 (vascular endothelial growth factor receptor) were co-expressed with a FLAG-tag fusion of murine (A), corresponding to amino acids 1418-1997 of the human enzyme, in which the catalytic domain had been mutated to create a trapping mutant. Co-immunoprecipitation with anti-FLAG antibodies and subsequent blotting of precipitates with appropriate enzyme-specific antibodies showed that Tie-2 was co-precipitated with the trapping mutant (but not with the wild-type phosphatase because the enzyme-substrate reaction is transient in this case). VEGFR2 was not co-precipitated with either wild-type or mutant phosphatase.
This study is based on the records of the patients who received laser-assisted frenectomy treatment due to mucogingival problems at pediatric dentistry department during two year period. Twenty-two patients treated with either Er,Cr:YSGG laser 2780 nm or 940 nm diode laser were selected who fulfilled the study's inclusion criteria. The analyzed data included age, gender, frenelum insertion type, type of dental laser, postoperative pain perception and wound healing. Post-operative pain was reported with Wong-Baker Faces Pain Rating Scale after 3 hours 1, 7 and 14 days. Wound surface healing was evaluated through photography. Images were uploaded to the software and the changes in the wound area were measured in square millimeters at the day of frenectomy and on days 1, 7, and 14 postoperatively.
PROBLEM TO BE SOLVED: To provide an information exchange system and an information exchange method which can surely refer to the information on patients with a small number of operations. SOLUTION: An input information 'in' is inputted to a keyboard 41 and the output information S41 is outputted from the keyboard 41. The information S41 is inputted to a transmission/reception protocol 42 and the output information S42a is outputted from the protocol 42. The information 42a is transmitted to a transmission/reception protocol 51 through a LAN 60, and the output information S51b is outputted from the protocol 51. The information 51b is inputted to an originating destination information conversion part 52, and an identifier S52 is outputted from the part 52 to specify a user serving as an originating destination out of the patient information included in the information S51b. The originating destinations are specified every time the patient information is inputted. The identifier S52 is stored in a memory 53.
PURPOSE:To provide the subject compound exhibiting a cold-sensation effect similar to menthol, not having sublimation properties, remarkably excellent in stability, free from a remarkable irritating odor because of its weak aroma and useful as a cold-sensation agent for a medicine, a cosmetic, etc. CONSTITUTION:A 3-substituted-p-menthane derivative of formula I (R is a 2 to 10C linear alkyl), e.g. menthanemethyl butylate. The above compound can be obtained, e.g. by reacting 3-hydroxymethyl-p-menthane of formula II with a carboxylic acid of formula R-COOH in the presence of an acid such as sulfuric acid at 50 to 150 deg.C for several to several score hours. In addition, the above reaction is carried out by using the carboxylic acid of formula R-COOH in an amount equimolar or excessive to the compound of formula II in benzene or toluene as the solvent while separating generated water from the reaction system by azeotropic distillation.
The patients will remain in bed supine with blindfolds. A volunteer will move close to the patient with hands behind and mentally repeat the alphabet or do count math during 5 minutes, around 8 weeks.
Beta thalassemia major it menifests after 6 months of life by severe anemia requiring life-long blood transfusion,which is the the gold standard therapy causing many complications including iron overload which associated to a certain extent with the generation of labile iron in the pathological red blood cell (RBC). The appearance of such forms of iron at the inner and outer cell surfaces exposes the cell to formation of reactive oxygen species (ROS),particularly the hydroxyl radical (·OH) serving as a Fenton reagent, Hydroxyl radical facilitated by membraneassociated iron might be particularly harmful because radical generation would be relatively sequestered from the cell antioxidant capacity and occur directly adjacent to lipid and protein membrane components exceeding cellular defense capacities causing oxidtive stress with prematre cell damage which is the main pathophysiological process in thalassemia . the fact that iron plays a major role in the generation of ROS implies that iron chelators can also serve as antioxidants. Obviously, chelation of iron is one of the major therapeutic goals in thalassemia. Consequently, the orally administered iron chelator deferiprone was able to remove free iron from β- thalassemic red cell membranes in a dose-related fashion, Deferiprone alleviated membrane damage possibly mediated by catalytic iron, such as In a few patients with Hb E/β thalassemia in Thailand, following administration of deferiprone alone for an average of 50 weeks, Hb levels increased concomitant with a decrease in transfusion requirement One possible explanation for this finding is that deferiprone acted like an antioxidant by removing excess free iron from the cells and, as a result, ROS generation was decreased. However, the antioxidant effect of this iron chelator by itself was not sufficient to neutralize the damage induced by ROS Moreover, oral administration of other antioxidant such as vitamin E, which is a lipid antioxidant, exhibited improvement in oxidant-antioxidant balance in the plasma . Another antioxidant that acts primarily on proteins is n_acetylcysteine, which improved certain parameters resulting from oxidative damage to sickle RBCs. here we will give the N_acetylcysteine orally in dose 10mg\\kg\\day to the thalassemic patients for 6 months and observing its effect as antioxidant on iron overload and the frequency in blood transfusion The ultimate purpose of all these observations is to try to design a combination of antioxidants consisting of an iron chelator, such as deferiprone, vitamin E as antioxidant for the lipids, and N-acetylcysteine as antioxidant for the proteins to decrease the deleterious effect of ORS.
Chinese medicine salvia is added into toothpaste which is then named after the salvia toothpaste or the salvia Chinese medicine toothpaste. Salvia such as salvia pellet which enjoys a good sale in the markets, etc. is a Chinese medicine which is often used for treating the cardiovascular and cerebrovascular diseases. Salvia has the functions of activating blood, dissolving stasis, cooling blood, relieving pain, regulating menstruation, cleaning heat for detumescence, calming heart for tranquillization, etc. The tooth-washing areas below the tongue and the oral cavity are one of the parts in which the human body can absorb the medical components rapidly, and thus many emergency patients are required to take medicines by sublingual administration. Due to the reason, people suitable to apply the salvia to treat or protect the health can receive the salvia medical treatment while cleaning the oral cavity by using the toothpaste to wash the teeth in the morning and night. In addition, the toothpaste manufacturers can segment market and increase the sale.
One dose (1 packet or 1 level teaspoon) of COLESTID Granules contains 5 grams of colestipol hydrochloride. One dose (1 packet or 1 level scoopful) of FLAVORED COLESTID Granules is approximately 7.5 grams powder which contains 5 grams of colestipol hydrochloride. The recommended daily adult dose is one to six packets or level scoopfuls given once or in divided doses. Treatment should be started with one dose once or twice daily with an increment of one dose/day at one- or two-month intervals. Appropriate use of lipid profiles as per NCEP guidelines including LDL-cholesterol and triglycerides is advised so that optimal, but not excessive doses are used to obtain the desired therapeutic effect on LDL-cholesterol level. If the desired therapeutic effect is not obtained at one to six doses/day with good compliance and acceptable side effects, combined therapy or alternate treatment should be considered.

To avoid accidental inhalation or esophageal distress, COLESTID and FLAVORED COLESTID should not be taken in its dry form. COLESTID and FLAVORED COLESTID should always be mixed with water or other fluids before ingesting. Patients should take other drugs at least one hour before or four hours after COLESTID or FLAVORED COLESTID to minimize possible interference with their absorption. (See PRECAUTIONS, Drug Interactions.)